888 related articles for article (PubMed ID: 28768872)
1. High-Risk Alphapapillomavirus Oncogenes Impair the Homologous Recombination Pathway.
Wallace NA; Khanal S; Robinson KL; Wendel SO; Messer JJ; Galloway DA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768872
[TBL] [Abstract][Full Text] [Related]
2. High-risk human papillomavirus oncogenes disrupt the Fanconi anemia DNA repair pathway by impairing localization and de-ubiquitination of FancD2.
Khanal S; Galloway DA
PLoS Pathog; 2019 Feb; 15(2):e1007442. PubMed ID: 30818369
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease.
Kennedy EM; Kornepati AV; Goldstein M; Bogerd HP; Poling BC; Whisnant AW; Kastan MB; Cullen BR
J Virol; 2014 Oct; 88(20):11965-72. PubMed ID: 25100830
[TBL] [Abstract][Full Text] [Related]
4. Genomic Signatures in HPV-Associated Tumors.
Hussain SS; Lundine D; Leeman JE; Higginson DS
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696429
[TBL] [Abstract][Full Text] [Related]
5. Beta human papillomavirus 8 E6 allows colocalization of non-homologous end joining and homologous recombination repair factors.
Hu C; Bugbee T; Dacus D; Palinski R; Wallace N
PLoS Pathog; 2022 Feb; 18(2):e1010275. PubMed ID: 35148356
[TBL] [Abstract][Full Text] [Related]
6. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy.
Hu Z; Ding W; Zhu D; Yu L; Jiang X; Wang X; Zhang C; Wang L; Ji T; Liu D; He D; Xia X; Zhu T; Wei J; Wu P; Wang C; Xi L; Gao Q; Chen G; Liu R; Li K; Li S; Wang S; Zhou J; Ma D; Wang H
J Clin Invest; 2015 Jan; 125(1):425-36. PubMed ID: 25500889
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus E7 oncoprotein targets RNF168 to hijack the host DNA damage response.
Sitz J; Blanchet SA; Gameiro SF; Biquand E; Morgan TM; Galloy M; Dessapt J; Lavoie EG; Blondeau A; Smith BC; Mymryk JS; Moody CA; Fradet-Turcotte A
Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19552-19562. PubMed ID: 31501315
[TBL] [Abstract][Full Text] [Related]
8. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo.
Jung HS; Erkin OC; Kwon MJ; Kim SH; Jung JI; Oh YK; Her SW; Ju W; Choi YL; Song SY; Kim JK; Kim YD; Shim GY; Shin YK
Int J Cancer; 2012 Apr; 130(8):1925-36. PubMed ID: 21630254
[TBL] [Abstract][Full Text] [Related]
9. HPV oncogenes expressed from only one of multiple integrated HPV DNA copies drive clonal cell expansion in cervical cancer.
Yu L; Majerciak V; Lobanov A; Mirza S; Band V; Liu H; Cam M; Hughes SH; Lowy DR; Zheng Z-M
mBio; 2024 May; 15(5):e0072924. PubMed ID: 38624210
[TBL] [Abstract][Full Text] [Related]
10. Assessment of human papillomavirus E6/E7 oncogene expression as cervical disease biomarker.
Fontecha N; Basaras M; Hernáez S; Andía D; Cisterna R
BMC Cancer; 2016 Nov; 16(1):852. PubMed ID: 27816058
[TBL] [Abstract][Full Text] [Related]
11. Homologous Recombination Repair Factors Rad51 and BRCA1 Are Necessary for Productive Replication of Human Papillomavirus 31.
Chappell WH; Gautam D; Ok ST; Johnson BA; Anacker DC; Moody CA
J Virol; 2015 Dec; 90(5):2639-52. PubMed ID: 26699641
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus type 16 E6 and E7 oncoproteins interact with the nuclear p53-binding protein 1 in an in vitro reconstructed 3D epithelium: new insights for the virus-induced DNA damage response.
Squarzanti DF; Sorrentino R; Landini MM; Chiesa A; Pinato S; Rocchio F; Mattii M; Penengo L; Azzimonti B
Virol J; 2018 Nov; 15(1):176. PubMed ID: 30445982
[TBL] [Abstract][Full Text] [Related]
13. Variations of human papillomavirus type 58 E6, E7, L1 genes and long control region in strains from women with cervical lesions in Liaoning province, China.
Liu JH; Lu ZT; Wang GL; Zhou WQ; Liu C; Yang LX; Sun ZR; Ruan Q
Infect Genet Evol; 2012 Oct; 12(7):1466-72. PubMed ID: 22659102
[TBL] [Abstract][Full Text] [Related]
14. DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri.
Melsheimer P; Vinokurova S; Wentzensen N; Bastert G; von Knebel Doeberitz M
Clin Cancer Res; 2004 May; 10(9):3059-63. PubMed ID: 15131043
[TBL] [Abstract][Full Text] [Related]
15. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
16. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis.
Wang-Johanning F; Lu DW; Wang Y; Johnson MR; Johanning GL
Cancer; 2002 Apr; 94(8):2199-210. PubMed ID: 12001118
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes.
Zhou J; Li B; Peng C; Wang F; Fu Z; Zhou C; Hong D; Ye F; Lü W; Xie X
Antiviral Res; 2013 May; 98(2):305-13. PubMed ID: 23523766
[TBL] [Abstract][Full Text] [Related]
19. RPRD1B is a potentially molecular target for diagnosis and prevention of human papillomavirus E6/E7 infection-induced cervical cancer: A case-control study.
Wen N; Bian L; Gon J; Meng Y
Asia Pac J Clin Oncol; 2021 Jun; 17(3):230-237. PubMed ID: 32866332
[TBL] [Abstract][Full Text] [Related]
20. Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes.
Nishida H; Matsumoto Y; Kawana K; Christie RJ; Naito M; Kim BS; Toh K; Min HS; Yi Y; Matsumoto Y; Kim HJ; Miyata K; Taguchi A; Tomio K; Yamashita A; Inoue T; Nakamura H; Fujimoto A; Sato M; Yoshida M; Adachi K; Arimoto T; Wada-Hiraike O; Oda K; Nagamatsu T; Nishiyama N; Kataoka K; Osuga Y; Fujii T
J Control Release; 2016 Jun; 231():29-37. PubMed ID: 26979870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
